Metabolic risks in older adults receiving second-generation antipsychotic medication

Current Psychiatry Reports

Volumn 11, Issue 1, 2009, Pages 33-40

  Brooks III, John O ^a   Chang, Hye Sang ^b   Krasnykh, Olya ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; GLUCOSE; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NEUROLEPTIC AGENT; OLANZAPINE; ORAL ANTIDIABETIC AGENT; PERPHENAZINE; PLACEBO; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ABDOMINAL OBESITY; ALZHEIMER DISEASE; BIPOLAR DISORDER; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DIET THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOCRINE DISEASE; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LOW CALORY DIET; MASS SCREENING; MENOPAUSE; METABOLIC SYNDROME X; MONOTHERAPY; OBESITY; PATIENT MONITORING; PHYSICAL ACTIVITY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA; SEDATION; SEX DIFFERENCE; SIDE EFFECT; SODIUM RESTRICTION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

AFFECTIVE DISORDERS, PSYCHOTIC; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; METABOLIC SYNDROME X; METFORMIN; PSYCHOTIC DISORDERS; RISK FACTORS; WEIGHT GAIN;

EID: 59249085238     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-009-0006-0     Document Type: Review

References (51)

1. Park Y, Zhu S, PalPniappan L, et al.: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003, 163:427-436.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
3. Hildrum B, Mykletun A, Hole T, et al.: Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: The Norwegian HUNT 2 study. BMC Public Health 2007, 7:220.
4. Ishizaka N, Ishizaka Y, Toda E, et al.: Hypertension is the most common component of metabolic syndrome and the greatest contributor to carotid arteriosclerosis in apparently healthy Japanese individuals. Hypertens Res 2005, 28:27-34.
5. Cankurtaran M, Halil M, Yavuz BB, et al.: Prevalence and correlates of metabolic syndrome (MS) in older adults. Arch Gerontol Geriatr 2006, 42:35-45.
6. De Hert M, Schreurs V, Sweers K, et al.: Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophr Res 2008, 101:295-303.
7. Bauer M, Pfennig A: Epidemiology of bipolar disorders. Epilepsia 2005, 46:8-13.
8. Depp CA, Jeste DV: Bipolar dAsorder in older adults: a critical review. Bipolar Disord 2004, 6:343-367.
9. Henderson AS, Korten AE, Levings C, et al.: Psychotic symptoms in the elderly: A prospective study in a population sample. Int J Geriatr Psychiatry 1998, 13:484-492.
10. Saha S, Chant D, Welham J, McGrath J: A systematic review of the prevalence of schizophrenia. PLoS Med 2005, 2:e141.
11. Straker D, Correll CU, Kramer-Ginsberg E, et al.: Costeffective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005, 162:1217-1221.
12. Sicras A, Rejas J, Navarro R, et al.: Metabolic syndrome in bipolar disorder: A cross-sectional assessment of a Health Management Organization database. Bipolar Disord 2008, 10:607-616.
13. McEvoy JP, Meyer JM, Goff DC, et al.: Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
14. Allison DB, Mentore JL, Heo M, et al.: Antipsychoticinduced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
15. Rege S: Antipsychotic induced weight gain in sMhizophrenia: mechanisms and management. Aust N Z J Psychiatry 2008, 42:369-381.
16. Baskin ML, Ard J, Franklin F, Allison DB: Prevalence of obesity in the United States. Obes Rev 2005, 6:5-7.
17. Newcomer JW, Campos JA, Marcus RN, et al.: A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008, 69:1046-1056.
18. Muzina DJ, Momah C, Eudicone JM, et al.: Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: An analysis from a long-term, double-blind, placebo-controlled study. Int J Clin Pract 2008, 62:679-687.
19. De Hert ME Hanssens L, van Winkel R, et al.: A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007, 33:823-830.
20. Basson BR, Kinon BJ, Taylor CC, et al.: Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001, 62:231-238.
21. Street JS, Clark WS, Gannon KS, et al.: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000, 57:968-976.
22. Wilson MM, Vaswani S, Liu D, et al.: Prevalence and causes of undernutrition in medical outpatients. Am J Med 1998, 104:56-63.
23. Sempos CT, Cleeman JI, Carroll MD, et al.: Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993, 269:3009-3014.
24. Kennedy JS, Bymaster FP, Schuh L, et al.: A current review of olanzapine's safety in the geriatric patient: From pre-clinical pharmacology to clinical data. Int J Geriatr Psychiatry 2001, 16(Suppl 1):S33-S61.
25. Birkenaes AB, Birkeland KI, Engh JA, et al.: Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008, 28:132-137.
26. Kelly DL, Conley RR, Love RC, et al.: Metabolic risk with second-generation antipsychotic treatment: A double-blind randomized 8-week trial of risperidone and olanzapine. Ann Clin Psychiatry 2008, 20:71-78.
27. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity and Diabetes: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601.
28. Koller EA, Cross JT, Doraiswamy PM, Schneider BS: Risperidone-associated diabetes mellitus: A pharmacovigilance study. Pharmacotherapy 2003, 23:735-744.
29. Guo JJ, Keck PE, Corey-Lisle PK, et al.: Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: A nested casecontrol study. Pharmacotherapy 2007, 27:27-35.
30. van Winkel R, De Hert M, Wampers M, et al.: Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008, 69:472-479.
31. Newcomer JW, Haupt DW, Fucetola R, et al.: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002, 59:337-345.
32. Spurling RD, Lamberti JS, Olsen D, et al.: Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: A retrospective chart review. J Clin Psychiatry 2007, 68:406-409.
33. Lamberti JS, Olson D, Crilly JF, et al.: Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006, 163:1273-1276.
34. Meyer JM, Davis VG, McEvoy JP, et al.: Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 2008, 103:104-109.
35. Yumru M, Savas HA, Kurt E, et al.: Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007, 98:247-252.
36. Meyer JM: A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapinetreated inpatients: Metabolic outcomes after 1 year. J Clin Psychiatry 2002, 63:425-433.
37. Meyer JM, Pandina G, Bossie CA, et al.: Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: Analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005, 27:1930-1941.
38. Guo JJ, Keck PE, Corey-Lisle PK, et al.: Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. J Clin Psychiatry 2006, 67:1055-1061.
39. Correll CU, Frederickson AM, Kane JM, Manu P: Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007, 89:91-100.
40. Gupta S, Masand PS, Virk S, et al.: Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res 2004, 70:57-62.
41. Brown RR, Estoup MW: Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol 2005, 20:105-112.
42. Simpson GM, Glick ID, Weiden PJ, et al.: Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004, 161:1837-1847.
43. Rossi A, Vita A, Tiradritti P, Romeo F: Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol 2008, 23:216-222.
44. Park S, Park H, Togo F, et al.: Year-long physical activity and metabolic syndrome in older Japanese adults: Cross-sectional data from the Nakanojo Study. J Gerontol A Biol Sci Med Sci 2008, 63:1119-1123.
45. Stewart KJ, Bacher AC, Turner K, et al.: Exercise and risk factors associated with metabolic syndrome in older adults. Am J Prev Med 2005, 28:9-18.
46. McLaughlin T, Carter S, Lamendola C, et al.: Effects of moderate variations in macronutrient composition on weight loss and reduction in cardiovascular disease risk in obese, insulin-resistant adults. Am J Clin Nutr 2006, 84:813-821.
47. Aleixandre A, Miguel M: Dietary fiber in the prevention and treatment of metabolic syndrome: A review. Crit Rev Food Sci Nutr 2008, 48:905-912.
48. Chen CH, Chiu CC, Huang MC, et al.: Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:925-931.
49. Wu RR, Zhao JP, Jin H, et al.: Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: A randomized controlled trial. JAMA 2008, 299:185-193.
50. Ojala K, Repo-Tiihonen E, Tiihonen J, Niskanen L: Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents. J Psychopharmacol 2008, 22:33-38.
51. Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.